This page lists all known medications that could potentially lead to 'Abnormal Erythropoiesis' as a side effect. It's important to note that mild side effects are quite common with medications. The ...

THE anemia of renal insufficiency is associated with both increased red-cell destruction and impaired erythropoietic response to anemia. Variations in the relative importance of these 2 mechanisms and ...

Please provide your email address to receive an email when new articles are posted on . Anemia in patients with cancer can be caused by a number of factors including blood loss, hemolysis, nutritional ...

For those affected by anemia, receiving the proper treatment can improve quality of life. The most common treatment is erythropoiesis-stimulating agents (ESAs), which can provide significant ...

Two hundred-billion red blood cells are renewed in our body every single day. These erythrocytes (also known as red blood cells) are generated from bi-potent megakaryocyte-erythroid progenitor cells ...

Erythropoietin (EPO) is a hormone predominantly produced in the kidney, which is then released into blood. Erythropoietin promotes the production of red blood cells (erythropoiesis) in the bone marrow ...

Please provide your email address to receive an email when new articles are posted on . In 1989, epoetin alfa was approved by the FDA to treat anemia resulting from chronic kidney disease. Epoetin ...

The primary literature review included 15 meta-analyses of RCTs and two RCTs. A growing body of evidence suggests that adding iron to treatment with an ESA may improve hematopoietic response and ...

Background: Erythropoiesis-stimulating agents are used to treat anemia in patients with cancer. However, their safety and effectiveness is controversial. We did a systematic review of the clinical ...

Will Prolyl Hydroxylase Inhibitors Supplant Erythropoiesis-Stimulating Agents and IV Iron in the Treatment of Chemotherapy-Induced Anemia? The following represents disclosure information provided by ...